# M1/M4 Agonist Relieved Schizophrenia Symptoms in Mid-Stage Trial

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/meetingcoverage/neicongress/123795) · 2026-11-09 · Medicine
Page: https://themorning.science/story/m1-m4-agonist-relieved-schizophrenia-symptoms-in-mid-stage-trial-e669545458473d60
Kind: research · Impact: medium

## In brief

- ML-007C-MA, an investigational muscarinic M1/M4 receptor agonist, is a combination of betovumeline and fesoterodine fumarate.
- In a mid-stage trial, it significantly improved schizophrenia symptoms in adults who had an acute exacerbation of psychosis.
- The source reports these trial data but is only a brief excerpt, so the full trial details are not available here.

## Why it matters

The result adds evidence that muscarinic M1/M4 agonism may treat schizophrenia symptoms, a mechanism distinct from current dopamine-focused antipsychotics. It is still an investigational mid-stage finding.

## Coverage

- [M1/M4 Agonist Relieved Schizophrenia Symptoms in Mid-Stage Trial](https://www.medpagetoday.com/meetingcoverage/neicongress/123795) — MedPageToday.com - medical news for physicians, 2026-11-09

Tags: schizophrenia, psychiatry, muscarinic receptors, clinical trial, drug development

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science